Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Price Target Raised to $27.00

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM – Get Rating) had its price target raised by Cantor Fitzgerald from $26.00 to $27.00 in a report published on Tuesday, The Fly reports. Cantor Fitzgerald also issued estimates for Actinium Pharmaceuticals’ FY2023 earnings at ($1.69) EPS. A number of other analysts have also recently issued reports on the company. William Blair […]

Related Keywords

New York ,United States ,William Blair ,Corton Capital Inc ,Actinium Pharmaceuticals Company Profile ,News Ratings For Actinium Pharmaceuticals Daily ,Actinium Pharmaceuticals Inc ,Actinium Pharmaceuticals ,Delphia United States Inc ,Actinium Pharmaceuticals Stock ,Man Group ,Hedge Funds Weigh In On Actinium Pharmaceuticals ,Cantor Fitzgerald ,Get Rating ,Actinium Pharmaceutical ,Antibody Radiation Conjugates ,Actinium Pharmaceuticals Daily ,Nyseamerican Atnm ,Atnm ,Medical ,Boost Price Target ,